Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton Jun 11, 2021 11:17am
130 Views
Post# 33372200

RE:RE:RE:RE:RE:This $3 BioTech Stock could EXPLODE SOON!! Why?

RE:RE:RE:RE:RE:This $3 BioTech Stock could EXPLODE SOON!! Why? This is just part of an experiment they are running on promo for the retail side. Spoke with them a couple weeks ago after someone had posted another video on this board, I wanted to check if it was in fact initiated by Antibe, they confirmed it was. Their focus remains on institutions however they are experimenting with online "influencers".
My suggestion to them was, there's no need to experiment, if you want to gain retail attention and that's the route you want to go, at least in part, perhaps reach out to the reddit crowd, those guys have numbers in the millions and can actually move stocks as we've all seen. That crowd is essentially moving shares of bankrupt companies that are catching 10x 20x share jumps, we actually have fundamentals to back up the promotion.


MrMugsy wrote:
TriumphSpitSix wrote: They paid that kid $1000 to make a 10 minute video and it might just be the best marketing/promo money they ever spent.


Hey ... I'm not knocking the video ... it was fun for existing shareholders to watch and I appreciate it being posted because it's killing some time for us.

But ... that's not going to gain us any traction going forward - IMO.  It carried pics and video clips that made 95% of the visual unrelated to ATE - just fluff that could have been added to almost any science discussion for a high school presentation.  The biggest benefit was the excitement in his voice but in the end ... he was just repeating what he understood from reading the presentation.

It's great that others are doing this ... just not where the company really needs to focus.

Product development, drug advancement and negotiations will drive our value in the short to medium term - IMO.  The two investors we should really focus on right now is the Institutional Investor and the drug partners.  The retail investor will just follow along once that happens.

Cheers to the rest of 2021 to get things done !!!



<< Previous
Bullboard Posts
Next >>